The Chief Scientific Officer and President of Glenmark Pharmaceuticals Swiss R&D Center elaborates on Glenmark’s endeavor to venture up the pharmaceutical value chain and discusses the company’s R&D strategy. Furthermore, he highlights the significance of strategic partnerships in today’s pharmaceutical R&D efforts.
You have spent 23 years working in large innovative pharmaceutical companies. What motivated you to join Glenmark?
"My mission is to lead the transformation from generics to innovation and specialty development, including ensuring that we have the right talent, infrastructure, footprint and core strategy."
